Literature DB >> 24476076

Posterior reversible encephalopathy syndrome due to malignant hypercalcemia: physiopathological considerations.

Carlos R Camara-Lemarroy1, Emmanuel I Gonzalez-Moreno, Jose de Jesus Ortiz-Corona, Sara G Yeverino-Castro, Monica Sanchez-Cardenas, Sagrario Nuñez-Aguirre, Miguel A Villarreal-Alarcon, Dionicio A Galarza-Delgado.   

Abstract

CONTEXT: Posterior reversible encephalopathy syndrome (PRES) is a neurological entity characterized by seizures, headache, and reversible subcortical vasogenic edema. It is associated with many etiologies, most often hypertension, chronic renal failure, and chemotherapy. Hypercalcemia is rarely associated with PRES.
OBJECTIVE: The aim of this study is to describe and discuss a case of PRES that developed in a patient with malignant hypercalcemia, with emphasis on the possible pathophysiological mechanisms involved. PATIENTS AND METHODS: A 38-year-old woman presented with altered mental status. She had a 2-month history of lumbar pain of moderate intensity, weight loss, and gastrointestinal complaints, in addition to a mass in her left breast. Her corrected serum calcium was 14.5 mg/dL. She was normotensive, had no focalizing signs, and her cerebrospinal fluid was normal. Despite treatment, her neurological state did not resolve, and she developed severe headaches at day 4 of her admission. Brain magnetic resonance imaging showed a bilateral and symmetric hyperintensity in the occipital and parietal lobes on T2-weighted and fluid-attenuated inversion recovery imaging, a characteristic highly suggestive of PRES. After correction of hypercalcemia, her symptoms and imaging abnormalities resolved.
CONCLUSIONS: The development of PRES in the setting of severe hypercalcemia is extremely rare. Hypercalcemia could lead to PRES in the absence of hypertension by various mechanisms, including vasospasm, endothelial dysfunction, and an inflammatory state. A high index of suspicion is needed in this setting because hypercalcemia can lead to neurological symptomatology, and prompt diagnosis is essential for adequate treatment.

Entities:  

Mesh:

Year:  2014        PMID: 24476076     DOI: 10.1210/jc.2013-3487

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Functional magnetic resonance imaging in primary hyperparathyroidism.

Authors:  Yunglin Gazes; Minghao Liu; Melissa Sum; Elaine Cong; Jennifer Kuo; James A Lee; Shonni Silverberg; Yaakov Stern; Marcella Walker
Journal:  Eur J Endocrinol       Date:  2020-07       Impact factor: 6.664

Review 2.  Hypercalcemia of Malignancy: An Update on Pathogenesis and Management.

Authors:  Aibek E Mirrakhimov
Journal:  N Am J Med Sci       Date:  2015-11

3.  A 39 year-old woman with milk-alkali syndrome complicated by posterior reversible encephalopathy syndrome.

Authors:  Khiem Vu; Gregory Becker; Donald Eagerton
Journal:  Bone Rep       Date:  2020-05-04

4.  Posterior reversible encephalopathy syndrome in a patient with HIV/AIDS and immune reconstitution syndrome: a case study and literature review.

Authors:  Zoe F Weiss; Josiah Rich; Edward J Wing
Journal:  Oxf Med Case Reports       Date:  2018-08-20

5.  Drp1 activates ROS/HIF-1α/EZH2 and triggers mitochondrial fragmentation to deteriorate hypercalcemia-associated neuronal injury in mouse model of chronic kidney disease.

Authors:  Hongming Sun; Xitong Li; Xin Chen; Yingquan Xiong; Yaochen Cao; Ziqiang Wang
Journal:  J Neuroinflammation       Date:  2022-09-01       Impact factor: 9.587

6.  Comment on "Posterior reversible encephalopathy syndrome in a patient with metastatic breast cancer: A case report".

Authors:  Suljo Kunić; Omer Ć Ibrahimagić; Biljana Kojić; Dževad Džananović
Journal:  World J Clin Cases       Date:  2022-08-26       Impact factor: 1.534

7.  Paraneoplastic PRES from lymphoma induced hypercalcemia: Case report and review of the literature.

Authors:  Khaled Moussawi; Ethan I Meltzer; Seth N Levin; Sashank Prasad
Journal:  eNeurologicalSci       Date:  2018-11-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.